JP2006519163A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006519163A5 JP2006519163A5 JP2004553807A JP2004553807A JP2006519163A5 JP 2006519163 A5 JP2006519163 A5 JP 2006519163A5 JP 2004553807 A JP2004553807 A JP 2004553807A JP 2004553807 A JP2004553807 A JP 2004553807A JP 2006519163 A5 JP2006519163 A5 JP 2006519163A5
- Authority
- JP
- Japan
- Prior art keywords
- csf
- antibody
- cancer
- antagonist
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42678102P | 2002-11-15 | 2002-11-15 | |
| US60/426,781 | 2002-11-15 | ||
| PCT/US2003/036679 WO2004045532A2 (en) | 2002-11-15 | 2003-11-17 | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010230108A Division JP2011006488A (ja) | 2002-11-15 | 2010-10-12 | 癌転移および癌転移に伴なう骨量減少を予防および処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006519163A JP2006519163A (ja) | 2006-08-24 |
| JP2006519163A5 true JP2006519163A5 (https=) | 2006-11-16 |
| JP4727992B2 JP4727992B2 (ja) | 2011-07-20 |
Family
ID=32326424
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004553807A Expired - Lifetime JP4727992B2 (ja) | 2002-11-15 | 2003-11-17 | 癌転移および癌転移に伴なう骨量減少を予防および処置するための方法 |
| JP2010230108A Withdrawn JP2011006488A (ja) | 2002-11-15 | 2010-10-12 | 癌転移および癌転移に伴なう骨量減少を予防および処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010230108A Withdrawn JP2011006488A (ja) | 2002-11-15 | 2010-10-12 | 癌転移および癌転移に伴なう骨量減少を予防および処置するための方法 |
Country Status (14)
| Country | Link |
|---|---|
| EP (3) | EP2246363A1 (https=) |
| JP (2) | JP4727992B2 (https=) |
| CN (1) | CN1787837A (https=) |
| AT (1) | ATE466885T1 (https=) |
| AU (1) | AU2003291002A1 (https=) |
| CA (1) | CA2505994A1 (https=) |
| CY (1) | CY1110305T1 (https=) |
| DE (1) | DE60332483D1 (https=) |
| DK (1) | DK1572106T3 (https=) |
| ES (1) | ES2345885T3 (https=) |
| IL (3) | IL168531A (https=) |
| PT (1) | PT1572106E (https=) |
| SI (1) | SI1572106T1 (https=) |
| WO (1) | WO2004045532A2 (https=) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| DE60332483D1 (de) | 2002-11-15 | 2010-06-17 | Novartis Vaccines & Diagnostic | Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| SI2311873T1 (sl) * | 2004-01-07 | 2018-12-31 | Novartis Vaccines And Diagnostics, Inc. | M-CSF-specifična monoklonska protitelesa in njihova uporaba |
| JP2007524671A (ja) * | 2004-01-21 | 2007-08-30 | カイロン コーポレイション | Ｍ−ｃｓｆムテインおよびその使用 |
| US20060024677A1 (en) * | 2004-07-20 | 2006-02-02 | Morris David W | Novel therapeutic targets in cancer |
| AR054428A1 (es) * | 2005-03-08 | 2007-06-27 | Pharmacia & Upjohn Co Llc | Composiciones de anticuerpos anti factor estimulante de colonia de macrofagos (anti-m-csf) que tienen menores niveles de endotoxina |
| ES2569409T3 (es) * | 2005-03-08 | 2016-05-10 | Pfizer Products Inc. | Composiciones de anticuerpo anti-CTLA-4 |
| EP2277916A3 (en) * | 2005-07-28 | 2011-04-27 | Novartis AG | Use of antibody to M-CSF |
| JP5457671B2 (ja) * | 2005-07-28 | 2014-04-02 | ノバルティス アーゲー | Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用 |
| CN101379400A (zh) * | 2005-12-22 | 2009-03-04 | 诺华有限公司 | 可溶性人m-csf受体及其应用 |
| CN101534858A (zh) * | 2006-01-05 | 2009-09-16 | 诺华有限公司 | 预防和治疗癌症转移和癌症转移相关性骨丢失的方法 |
| PL2188313T3 (pl) * | 2007-08-21 | 2018-04-30 | Amgen, Inc. | Białka wiążące ludzki antygen c-fms |
| US8183207B2 (en) | 2008-11-26 | 2012-05-22 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules |
| WO2010062399A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Csf1r extracellular domain fusion molecules and treatments using same |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| AR080698A1 (es) * | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| DK2734547T3 (en) | 2011-07-18 | 2017-04-03 | Univ Melbourne | USE OF C-FMS ANTIBODIES |
| US20140288279A1 (en) | 2011-10-21 | 2014-09-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | M-DC8+ Monocyte Depleting Agent for the Prevention or the Treatment of a Condition Associated with a Chronic Hyperactivation of the Immune System |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| WO2013126617A1 (en) * | 2012-02-22 | 2013-08-29 | The Regents Of The University Of Colorado, A Body Corporate | Bouvardin derivatives and therapeutic uses thereof |
| US9452215B2 (en) | 2012-02-22 | 2016-09-27 | The Regents Of The University Of Colorado | Bourvadin derivatives and therapeutic uses thereof |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| JP5799048B2 (ja) * | 2013-03-26 | 2015-10-21 | 株式会社三共 | 遊技機 |
| EA031471B1 (ru) | 2013-04-12 | 2019-01-31 | МорфоСис АГ | Антитела, направленные на m-csf |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| AU2015254542A1 (en) * | 2014-04-30 | 2016-11-17 | Biomerix Corporation | Agent, product and use |
| SG11201610672YA (en) | 2014-06-23 | 2017-01-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| EP3212670B1 (en) | 2014-10-29 | 2020-12-23 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| MX2017008218A (es) | 2014-12-22 | 2017-10-18 | Five Prime Therapeutics Inc | Anticuerpos anti-csf1r para tratar pvns. |
| EA035817B1 (ru) | 2015-03-10 | 2020-08-14 | Адуро Байотек, Инк. | Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона" |
| AU2016249981B2 (en) | 2015-04-13 | 2022-02-17 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| EP3108897A1 (en) | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| HRP20211058T8 (hr) | 2015-07-29 | 2021-11-26 | Novartis Ag | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 |
| PE20181326A1 (es) | 2015-11-03 | 2018-08-20 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| CN109790220A (zh) | 2016-08-25 | 2019-05-21 | 豪夫迈·罗氏有限公司 | 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药 |
| CN110072553B (zh) | 2016-12-22 | 2023-09-15 | 豪夫迈·罗氏有限公司 | 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗 |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| MY204117A (en) | 2017-06-22 | 2024-08-08 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| MX2020002303A (es) | 2017-08-30 | 2020-09-10 | Beijing Xuanyi Pharmasciences Co Ltd | Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon. |
| EP3681535A1 (en) | 2017-09-13 | 2020-07-22 | Five Prime Therapeutics, Inc. | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer |
| CN111655288A (zh) | 2017-11-16 | 2020-09-11 | 诺华股份有限公司 | 组合疗法 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN113490528B (zh) | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| CN109970852B (zh) * | 2019-04-01 | 2020-10-13 | 浙江大学 | 分泌抗狂犬病毒m蛋白单克隆抗体的杂交瘤细胞株及应用 |
| CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
| BR112022011902A2 (pt) | 2019-12-20 | 2022-09-06 | Novartis Ag | Terapias de combinação |
| CN111053903A (zh) * | 2019-12-26 | 2020-04-24 | 深圳市纳诺艾医疗科技有限公司 | 一种携带共振原子的核酸类似物的化合物的应用 |
| KR20230027056A (ko) | 2020-06-23 | 2023-02-27 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 |
| JP7819176B2 (ja) | 2020-08-03 | 2026-02-24 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| WO2022073127A1 (en) * | 2020-10-07 | 2022-04-14 | Tatum Bioscience Inc. | Live biotherapeutics secreting synthetic bacteriophages in the treatment of cancer |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US6117422A (en) * | 1985-02-05 | 2000-09-12 | Chiron Corporation | N∇2-CSF-1(long form) and carboxy truncated fragments thereof |
| US4847201A (en) | 1985-02-05 | 1989-07-11 | Cetus Corporation | DNA encoding for CSF-1 and accompanying recombinant systems |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5032676A (en) | 1986-10-14 | 1991-07-16 | Immunex Corporation | Nonglycosylated analogs of human colony stimulating factors |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4929700A (en) | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DK0457804T3 (da) * | 1989-02-10 | 1996-09-23 | Chiron Corp | M-CSF-monoklonale antistoffer, som genkender en neutraliserende, konformational epitop |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| GB8915572D0 (en) | 1989-07-07 | 1989-08-23 | Natural Environment Res | Use of bluetongue virus proteins as vaccine components |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5650554A (en) | 1991-02-22 | 1997-07-22 | Sembiosys Genetics Inc. | Oil-body proteins as carriers of high-value peptides in plants |
| JP3417558B2 (ja) | 1991-05-10 | 2003-06-16 | ジェネンテク，インコーポレイテッド | 配位子作用薬および拮抗薬の選択 |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| WO1993016177A1 (en) | 1992-02-11 | 1993-08-19 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| JP3628713B2 (ja) | 1993-06-07 | 2005-03-16 | 帝國製薬株式会社 | 生理学的に活性なペプチドを含有する膣投与製剤 |
| US5585277A (en) | 1993-06-21 | 1996-12-17 | Scriptgen Pharmaceuticals, Inc. | Screening method for identifying ligands for target proteins |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| US5443953A (en) | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
| DE19502584C2 (de) | 1994-01-28 | 1999-08-12 | Medigene Ag Ges Fuer Molekular | Verfahren zur Bestimmung der Aktivität eines regulatorischen Faktors sowie Verwendung dieses Verfahrens |
| US6054287A (en) | 1994-05-27 | 2000-04-25 | Methodist Hospital Of Indiana, Inc. | Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species |
| US20020111461A1 (en) | 1999-05-21 | 2002-08-15 | Todd C. Somers | Low molecular weight peptidomimetic growth hormone secretagogues |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6025146A (en) * | 1995-06-05 | 2000-02-15 | Chiron Corporation | Identification of M-CSF agonists and antagonists |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| GB9712818D0 (en) | 1996-07-08 | 1997-08-20 | Cambridge Antibody Tech | Labelling and selection of specific binding molecules |
| DK0934526T3 (da) | 1996-10-08 | 2003-05-05 | Bisys B V U | Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| US6017757A (en) | 1997-02-20 | 2000-01-25 | Mississippi State University | Isolated viable nematode intestinal cells |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| WO1999029345A1 (en) * | 1997-12-05 | 1999-06-17 | La Jolla Institute For Experimental Medicine | Inhibition of tumor growth by macrophage intervention |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| HK1044159A1 (zh) | 1998-12-01 | 2002-10-11 | 蛋白质设计实验室股份有限公司 | 抗γ-干扰素的人化抗体 |
| WO2001030381A2 (de) | 1999-10-28 | 2001-05-03 | Hofbauer, Reinhold | Verwendung von csf-1-inhibitoren |
| US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| US20030199531A1 (en) | 2001-07-19 | 2003-10-23 | Todd Wipke | YIGSR peptidomimetics and methods for using the same |
| PT1527100E (pt) | 2002-03-29 | 2009-08-25 | Schering Corp | Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos |
| US20030198965A1 (en) | 2002-04-19 | 2003-10-23 | Isis Pharmaceuticals Inc. | Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression |
| DE60332483D1 (de) | 2002-11-15 | 2010-06-17 | Novartis Vaccines & Diagnostic | Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust |
-
2003
- 2003-11-17 DE DE60332483T patent/DE60332483D1/de not_active Expired - Lifetime
- 2003-11-17 ES ES03783587T patent/ES2345885T3/es not_active Expired - Lifetime
- 2003-11-17 AU AU2003291002A patent/AU2003291002A1/en not_active Abandoned
- 2003-11-17 DK DK03783587.3T patent/DK1572106T3/da active
- 2003-11-17 EP EP10004581A patent/EP2246363A1/en not_active Withdrawn
- 2003-11-17 EP EP10178225.8A patent/EP2287192B1/en not_active Revoked
- 2003-11-17 JP JP2004553807A patent/JP4727992B2/ja not_active Expired - Lifetime
- 2003-11-17 AT AT03783587T patent/ATE466885T1/de active
- 2003-11-17 SI SI200331835T patent/SI1572106T1/sl unknown
- 2003-11-17 CN CNA2003801088289A patent/CN1787837A/zh active Pending
- 2003-11-17 CA CA002505994A patent/CA2505994A1/en not_active Abandoned
- 2003-11-17 EP EP03783587A patent/EP1572106B1/en not_active Expired - Lifetime
- 2003-11-17 PT PT03783587T patent/PT1572106E/pt unknown
- 2003-11-17 WO PCT/US2003/036679 patent/WO2004045532A2/en not_active Ceased
-
2005
- 2005-05-11 IL IL168531A patent/IL168531A/en not_active IP Right Cessation
-
2009
- 2009-05-21 IL IL198884A patent/IL198884A/en not_active IP Right Cessation
-
2010
- 2010-04-11 IL IL204987A patent/IL204987A/en not_active IP Right Cessation
- 2010-07-20 CY CY20101100680T patent/CY1110305T1/el unknown
- 2010-10-12 JP JP2010230108A patent/JP2011006488A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4727992B2 (ja) | 癌転移および癌転移に伴なう骨量減少を予防および処置するための方法 | |
| JP2006519163A5 (https=) | ||
| US12466894B2 (en) | Anti-MUC16 antibodies and uses thereof | |
| JP6305964B2 (ja) | Ｉｌ−２２に結合する抗体およびｉｌ−２２ｒに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法 | |
| CN104662044B (zh) | 用于治疗ror1癌症并抑制转移的抗体和疫苗 | |
| JP5328156B2 (ja) | オンコスタチンｍレセプターに対する抗体 | |
| JP5328155B2 (ja) | Ａｄａｍ−９モジュレータ | |
| AU2019215202A1 (en) | Antibodies to Galectin-3 and methods of use thereof | |
| CN101379087B (zh) | 用于治疗与细胞因子信号传导相关的疾病和病症、牵涉与il-22和il-22r结合的抗体的组合物和方法 | |
| HK1150292A (en) | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis | |
| HK1153756A (en) | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis | |
| HK1092717A (en) | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis | |
| BR112017019978B1 (pt) | Anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, polinucleotídeo, vetor, célula microbiana transgênica ex vivo, método para produzir uma célula transgênica ex vivo, método para produzir um anticorpo, composição farmacêutica e uso do anticorpo |